Onkologie. 2014:8(3):117-120

Current treatment approaches in patients with advanced-stage Hodgkin lymphoma

Heidi Móciková

Interní hematologická klinika, FN Královské Vinohrady, Praha

3. lékařská fakulta Univerzity Karlovy v Praze

More than 80 % of patients with Hodgkin lymphoma (HL) younger than 60 years are likely to be cured with modern treatment strategies. The

goal of current treatment approaches is to maintain the high treatment efficacy and to reduce the toxicity. BEACOPP escalated has a 10 %

overall survival advantage over ABVD in patients with advanced-stage HL, therefore 6 cycles of BEACOPP escalated has become the standard

of care for patients younger than 60 years. Six cycles of ABVD remain the standard of care for patients over 60 years. Radiotherapy could be

omitted in patients with a negative positrone emission tomography (PET) finding after chemotherapy. Mature trial results of the treatment

stratification based on PET and trial results of brentuximab vedotin combined with chemotherapy in the first-line treatment are awaited.

Keywords: Hodgkin lymphoma, ABVD, BEACOPP, FDG-PET, brentuximab vedotin

Published: June 1, 2014  Show citation